The story has been updated to include comments from Vermillion's conference call on Thursday.

NEW YORK (Genomeweb News) – Vermillion reported after the close of the market Thursday that its third quarter revenues were up 3 percent year over year at $330,000 versus $319,000 in Q3 2012.

The company posted product revenue of $216,000, up 5 percent from $205,000 year over year. That revenue was based on 4,328 OVA1 ovarian cancer tests performed in Q3 2013 versus 4,100 tests performed in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Nov
15
Sponsored by
Twist Bioscience

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.